



**MIRAGEN THERAPEUTICS TO REPORT THIRD QUARTER 2019 FINANCIAL RESULTS  
AND HOST A CONFERENCE CALL**

**BOULDER, Colo., October 22, 2019** – miRagen Therapeutics, Inc. (NASDAQ: MGEN), a clinical-stage biopharmaceutical company developing proprietary RNA-targeted therapies with a specific focus on microRNAs, will host a conference call and webcast on Thursday, November 7<sup>th</sup>, at 4:30 p.m. ET to discuss a corporate update and results for the third quarter of 2019.

To access the call, please dial 855-327-6837 in the U.S. or 631-891-4304 outside the U.S. and provide the conference ID number: 10007827. A live webcast can be accessed from the Investors and Media section of the miRagen Therapeutics website. A replay of this conference call will be available on miRagen's website approximately one hour after the event.

**About miRagen Therapeutics, Inc.**

miRagen Therapeutics, Inc. is a clinical-stage biopharmaceutical company discovering and developing proprietary RNA-targeted therapies with a specific focus on microRNAs and their role in diseases where there is a high unmet medical need. miRagen has three clinical stage product candidates, cobomarsen, remlarsen, and MRG-110. miRagen's clinical product candidate for the treatment of certain cancers, cobomarsen, is an inhibitor of microRNA-155, which is found at abnormally high levels in malignant cells of several blood cancers. miRagen's clinical product candidate for the treatment of pathological fibrosis, remlarsen, is a replacement for microRNA-29, which is found at abnormally low levels in a number of pathological fibrotic conditions, including cutaneous, cardiac, renal, hepatic, pulmonary and ocular fibrosis, as well as in systemic sclerosis. MRG-110, an inhibitor of microRNA-92, is miRagen's product candidate for the treatment of heart failure and other ischemic disease. In addition to these programs, miRagen is developing a pipeline of preclinical product candidates. The goal of miRagen's translational medicine strategy is to progress rapidly to first-in-human studies once it has established the pharmacokinetics, pharmacodynamic, safety, and manufacturability of the product candidate in preclinical studies. For more information and scientific presentations, please visit [www.miragen.com](http://www.miragen.com). For information on clinical trials please visit [www.clinicaltrials.gov](http://www.clinicaltrials.gov).

**Investor Relations Contact:**

Dan Ferry  
LifeSci Advisors

(617) 430-7576

[daniel@lifesciadvisors.com](mailto:daniel@lifesciadvisors.com)